STOCK TITAN

Galera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that its CEO, Mel Sorensen, M.D., will present at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 1:50 p.m. ET. A live webcast of the presentation will be available on the company's Investors page, with an archived version accessible for 30 days post-event.

Galera is focused on developing innovative therapies for cancer treatment, including avasopasem manganese (GC4419), aimed at reducing radiation-induced oral mucositis. The drug is under various trials, including Phase 3 and Phase 2 studies.

Positive
  • None.
Negative
  • None.

MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021, at 1:50 p.m. ET.

A live webcast of the presentation will be accessible from the Investors page of Galera’s website, investors.galeratx.com. An archived version of the webcast will be available in the News & Events section of the Investors page of Galera’s website for 30 days following the event.

About Galera Therapeutics

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial to assess its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication. It is also being studied in the EUSOM Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, the AESOP Phase 2a trial to assess its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer, and a Phase 2 trial in hospitalized patients who are critically ill with COVID-19. A pilot Phase 1/2 trial of avasopasem in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC) has completed enrollment and reported interim results, with follow-up ongoing. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera’s second dismutase mimetic product candidate, GC4711, is being developed specifically to augment the anti-cancer efficacy of SBRT, and is currently being studied in the GRECO-1 Phase 1/2 trial in combination with SBRT in patients with non-small cell lung cancer. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.

Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com

Jennifer Porcelli
Solebury Trout
646-378-2962
jporcelli@soleburytrout.com

Media Contact:
Heather Anderson
6 Degrees
919-827-5539
handerson@6degreespr.com 


FAQ

When will the CEO of Galera Therapeutics present at the Oppenheimer Healthcare Conference?

Mel Sorensen, CEO of Galera Therapeutics, will present on March 17, 2021, at 1:50 p.m. ET.

How can I watch the Galera Therapeutics presentation at the conference?

The presentation will be streamed live on Galera's Investors page, with a recorded version available for 30 days after the event.

What is avasopasem manganese and its significance?

Avasopasem manganese (GC4419) is a drug being developed by Galera to reduce radiation-induced severe oral mucositis in cancer patients.

What trials is Galera Therapeutics currently conducting with avasopasem?

Galera is conducting several trials, including the Phase 3 ROMAN trial and EUSOM Phase 2a trial, among others.

What designations has the FDA granted to avasopasem manganese?

Avasopasem manganese has received Fast Track and Breakthrough Therapy designations from the FDA for reducing radiation-induced oral mucositis.

GALERA THERAPEUTICS INC

OTC:GRTX

GRTX Rankings

GRTX Latest News

GRTX Stock Data

6.52M
54.39M
31.63%
1.07%
3.9%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MALVERN